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ABSTRACT
A short abnormal polyalanine expansion in the
polyadenylate-binding protein nuclear-1 (PABPN1)
protein causes oculopharyngeal muscular dystro-
phy (OPMD). Mutated PABPN1 proteins accumulate
as insoluble intranuclear aggregates in muscles of
OPMD patients. While the roles of PABPN1 in nu-
clear polyadenylation and regulation of alternative
poly(A) site choice have been established, the molec-
ular mechanisms which trigger pathological defects
in OPMD and the role of aggregates remain to be
determined. Using exon array, for the first time we
have identified several splicing defects in OPMD.
In particular, we have demonstrated a defect in the
splicing regulation of the muscle-specific Troponin
T3 (TNNT3) mutually exclusive exons 16 and 17 in
OPMD samples compared to controls. This splicing
defect is directly linked to the SC35 (SRSF2) splicing
factor and to the presence of nuclear aggregates. As
reported here, PABPN1 aggregates are able to trap
TNNT3 pre-mRNA, driving it outside nuclear speck-
les, leading to an altered SC35-mediated splicing.
This results in a decreased calcium sensitivity of
muscle fibers, which could in turn plays a role in mus-
cle pathology. We thus report a novel mechanism of
alternative splicing deregulation that may play a role
in various other diseases with nuclear inclusions or
foci containing an RNA binding protein.
INTRODUCTION
The poly(A) RNA binding protein, polyadenylate-binding
protein nuclear 1 (PABPN1), is a ubiquitous protein, that
binds virtually all mRNAs and plays key roles in post-
transcriptional processing of RNA (1). PABPN1 activates
poly(A) polymerase (PAP) and controls poly(A) tail length
on RNA transcripts (2–4). In addition, PABPN1 regulates
the use of alternative polyadenylation (APA) sites (5,6),
which in turn controls mRNA levels and stability. PABPN1
is also involved in the regulation of the processing of long
non-coding RNAs (lncRNAs) (7) and nuclear surveillance,
leading to hyperadenylation and decay of RNA (8). It has
recently been shown that PABPN1 regulates human telom-
erase 3′ end RNA maturation (9). A short (1–8) and mei-
otically stable GCN trinucleotide repeat expansion in the
coding region of the PABPN1 gene causes oculopharyn-
geal muscular dystrophy (OPMD) (10–12), a late and pro-
gressive autosomal dominant inherited neuromuscular dis-
order. OPMD is characterised by progressive eyelid droop-
ing, swallowing difficulties (as pharyngeal and cricopharyn-
geal muscles aremost affected) and proximal limbweakness
(13).
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OPMD belongs to the group of triplet expansion dis-
eases (14,15); the translation of the PABPN1 allele contain-
ing expanded repeats (expPABPN1) leads to a pathogenic
polyalanine tract at the N-terminal of the protein and the
formation of PABPN1 intranuclear aggregates in muscle
fibers (16). These aggregates in addition to PABPN1 con-
tain several proteins such as ubiquitin, proteasome sub-
units, heat-shock proteins, splicing factors, poly(A) poly-
merase (PAP) as well as poly(A) RNA (17–19). How-
ever these insoluble aggregates also exclude cleavage and
polyadenylation specific factor subunits (CPSF), splicing
factors such as SC35 and the cytoplasmic poly(A) binding
protein (PABPC) (19). The expanded polyalanine tract in
PABPN1 is thought to induce protein misfolding and con-
sequently the formation of aggregates, which are targeted
to the ubiquitin-proteasome degradation pathway (20,21).
Although the presence of aggregates in skeletal muscles is a
pathological hallmark of OPMD, their exact role in the dis-
ease remains controversial. Several studies have suggested a
pathological function for nuclear aggregates e.g. sequestrat-
ing essential cellular components including PABPN1 itself
(17–18,22). This is supported by the fact that a higher fre-
quency of nuclear aggregates is observed in severe homozy-
gous patients (23) andmuscle function is improvedwhen the
number of aggregates is reduced (24–26). In contrast, other
studies have suggested that the aggregatesmay just be the re-
sult of a cellular defence mechanism (27) and not the direct
cause of the disease with the soluble form of the mutated
PABPN1 being itself pathogenic (28,29). Apoptosis and
deregulation of the ubiquitin-proteasome system have also
been proposed as downstream events triggered by the aggre-
gates (20,30). Recently we demonstrated a global deregula-
tion of nuclear-encoded mitochondrial RNA in OPMD pa-
tients and animal models, implicating mRNA poly(A) tail
regulation via the recruitment of Smaug RNA binding pro-
tein as an upstream event (31).
Over the last years, the following observations have sug-
gested that splicing defects may occur in OPMD: (i) the
identification of splicing factors in aggregates (17–18,22);
(ii) the fact that, using literature-aided analyses, the terms
‘RNA splicing’ and ‘alternative splicing’ were biomedical
concepts highly associatedwith humanOPMD-deregulated
genes (20); (iii) two recent studies have suggested a role
for PABPN1 in splicing regulation (32,33). However, no
such mechanism has yet been described. Alternative splic-
ing (AS) produces a highly dynamic proteome, whose di-
versity is regulated in a developmental and tissue-specific
manner (34). More than 90% of human protein-encoding
genes create multiple mRNA isoforms by AS. This post-
transcriptional mechanism generates diversity and is tightly
regulated, with both cis- and trans-acting elements. Defects
in RNA splicing processes, such as mutations in cis-acting
splicing elements or in trans-acting splicing factors, have
emerged as a common disease-causing mechanism (35,36).
Skeletal muscle is a highly plastic tissue, adapting its struc-
ture and metabolism in response to diverse conditions such
as contractile activity, mechanical overload and nutrients.
Skeletal muscle is one of the tissues with the highest number
of alternative splicing events, highlighting a high degree of
complexity (37–39). In particular, alterations of alternative
splicing events have been largely described in several mus-
cular dystrophies (40,41).
In this work, we provide the first proof that splicing de-
fects occur in OPMD and describe a novel mechanism in-
volved in at least one of these defects and how this defect
is related to muscle function. Interestingly, we demonstrate
that in OPMD the mutually exclusive exons of TNNT3
mRNA are misspliced with an imbalanced ratio of the two
resulting isoforms. Using a minigene construct, we show
that SC35 regulates the splicing of these mutually exclusive
exons. We further demonstrated that PABPN1 aggregates
are able to sequester a pre-mRNA. Taking these results to-
gether, we propose that this splicing defect results from the
delocalization of the mRNA, trapped in pathological ag-




For the whole-genome microarray study, we selected skele-
tal muscle (sternocleidomastoid) biopsies from OPMD pa-
tients (n = 4) and control (n = 4) individuals (Table 1).
All patients were aged between 54 and 91 years of age at
the time of muscle biopsy. For downstream analysis, we
used additional muscle biopsies (sternocleidomastoid and
quadriceps) from control (aged 44–91) and OPMD (aged
52–82) patients. All samples generated from these biopsies
were compared individually and not pooled before the anal-
ysis. OPMD patients showed typical clinical phenotype and
the nature of the PABPN1 mutation was confirmed by ge-
netic studies. All muscle biopsies were obtained during sur-
gical procedure after informed consent in accordance with
the French legislation on ethical rules.
RNA isolation and Affymetrix exon array data processing
Total RNA was extracted from snap frozen skeletal mus-
cle biopsies using Trizol (Invitrogen) according to the man-
ufacturer’s instructions. RNA samples were quantified us-
ing a ND-1000 NanoDrop spectrophotometer (NanoDrop
Technologies) and purity/integrity were assessed using dis-
posable RNA chips (Agilent RNA 6000 Nano LabChip
kit) and an Agilent 2100 Bioanalyzer (Agilent Technolo-
gies,Waldbrunn,Germany). The averageRIN value of total
RNAs was 7.16 (6.1–7.8). Each RNA (n = 8; four controls
and four OPMD) was analyzed individually. Affymetrix
Human Exon 1.0 ST arrays were hybridized by GenoSplice
technology (www.genosplice.com) according the Ambion
WT protocol (Life technologies, France) and Affymetrix
(Santa Clara, CA, USA) labelling and hybridization rec-
ommendations. Raw data were controlled with the Expres-
sion console (Affymetrix). Affymetrix Human Exon 1.0 ST
Array dataset analysis and visualization were made using
EASANA® (GenoSplice technology), which is based on
theGenoSplice’s FASTDB® annotations (42). ExonArray
data were normalized using quantile normalization. Back-
ground correctionsweremadewith antigenomic probes and
probes were selected as described previously (43,44). Only
probes targeting exons annotated from FAST DB® tran-
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Table 1. Skeletal muscle biopsies from control (CTRL) and aged-matched OPMD patients (n = 4 per group) were used for the study. M: male; F: female
Patient Age Gender Genotype
OPMD 54 M (GCN)13/Ala13
OPMD 61 F (GCN)14/Ala14
OPMD 81 M (GCN)12/Ala12
OPMD 83 M (GCN)13/Ala13
CTRL 44 F (GCN)10/Ala10
CTRL 61 M (GCN)10/Ala10
CTRL 88 M (GCN)10/Ala10
CTRL 91 M (GCN)10/Ala10
mRNA sequences are in public databases (42,45). Bad-
quality selected probes (e.g. probes labelled by Affymetrix
as ‘cross-hybridizing’) and probes whose intensity signal
was too low compared to antigenomic background probes
with the same GC content were removed from the analy-
sis. Only probes where the detection above background was
with a P value ≤0.05 in at least half of the arrays were con-
sidered for statistical analysis (43,44). Only genes expressed
in at least one compared condition were analyzed. To be
considered expressed, the DABG P-value had to be ≤0.05
for at least half of the gene probes. We performed an un-
paired Student’s t-test to compare gene intensities in the dif-
ferent biological replicates. Genes were considered to be sig-
nificantly regulated when the fold-change was≥1.5 and un-
corrected P-value ≤0.05. Statistical analyses were also per-
formed using the Student’s unpaired t-test on the splicing
index to analyze the Exon Array data as described previ-
ously (43,44). The splicing index corresponds to a compar-
ison of gene-normalized exon intensity values between the
two analyzed experimental conditions. Results were consid-
ered statistically significant for uncorrected P-values ≤0.05
and fold-changes ≥2.0.
To filter and classify exons predicted to be differentially
included, manual inspection was performed after upload-
ing the Exon Array data into the EASANA® visualiza-
tion module, which is based on the FAST DB® Client Edi-
tion annotations. By computational comparison of publicly
available mRNA sequences with genomic sequences, alter-
native exons were annotated in FAST DB® as alternative
first exons, alternative terminal exons, cassette exons, mu-
tually exclusive exons, alternative 5′ donor sites, alternative
3′ acceptor sites, intron retention and exonic internal dele-
tion (Supplementary Figure S1 and Table S1).
RT-PCR and Real-time qRT-PCR
RNA (50–250 ng for muscle biopsies, 1–3g for cell pellets)
was reverse transcribed usingM-MLV reverse transcriptase
(Invitrogen) according to the manufacturer’s instructions.
The splicing of TNNT3 mRNA was observed with 1 l of
cDNA for PCR using Reddy mix polymerase (Thermo Sci-
entific) according to the manufacturer’s instructions, and
primers located within TNNT3 exon 15, TNNT3 exon 16
and TNNT3 exon 17 (sequences information listed in Sup-
plementary Table S2). The reaction mixture was heated to
94◦C for 5 min and followed by 35 PCR cycles: 15 s at 94◦C,
15 s at 55◦C and 15 s at 72◦C followed by a last elongation
step at 72◦C for 7 min. PCR products from alternatively
spliced TNNT3mRNAs, which are 108 and 131 bp, respec-
tively, were resolved on 5% non-denaturing polyacrylamide
ethydium bromide stained gels.
cDNA was used for quantitative PCR reaction using
SYBR green mix buffer (LightCycler® 480 Sybr green I
Master) in a total reaction volume of 9 l. The PCR re-
action was carried out as follows: 8 min at 95◦C followed
by 50 cycles of the following: 15 s at 95◦C, 15 s at 60◦C and
15 s at 72◦C. Specificity of the PCR products was checked
bymelting curve analysis using the following program: 65◦C
increasing by 0.11◦C/s to 97◦C. The expression level of each
mRNAwas normalized to that of humanB2MmRNA (-2
microglobulin) or murine RPLP0 mRNA (large ribosomal
protein, subunit P0) expression. Expression levels were cal-
culated according to the Ct method.
The sequences of primers used for RT-PCR and for real-
time qRT-PCR are listed in Supplementary Table S2.
Plasmid construction
The human TNNT3 minigene (3881 bp) was prepared
by amplifying the human TNNT3 genomic region be-
tween exon 15 and exon 18 with the Platinium® Taq
DNA Polymerase High Fidelity (Invitrogen) following the
manufacturer’s instruction and using the primers FWD:
5′-AAAACTTAAGGGACAAGGCCAAGGAGCTCT-3′
containing the AflII restriction site (in bold) and REV:
5′-ACCGGAATTCTGAAGGGGGTTCTGCAGCTTT-3′
containing the EcoRI site (in bold). The PCR product
was digested by AflII and EcoRI and inserted into the
pCDNA3.1+ (Invitrogen) at the corresponding restriction
sites.
The murine Tnnt3 minigene (3476 bp) was prepared us-
ing the same protocol by amplifying the murine Tnnt3 ge-
nomic region between exon 15 and 18 using the following
primers fwd: 5′-AAAACTTAAGGGACAAGGCCAAGG
AACTCTG-3′ and rev: 5′ ACCGGAATTCGGGAGTCT
GATAACTTTATTCCT3′.
Cell culture and transfection
Human embryonic kidney HEK293T cells were grown
in Dulbecco’s modified Eagle’s medium (DMEM) supple-
mented with 10% foetal calf serum (Life Technologies) and
50g/ml gentamicin (Life Technologies) in a 5%CO2 incu-
bator at 37◦C. Cells were grown in six-well plates and were
transfected at 80% confluence with 5.2 g of DNA con-
structs using PEI in 150 mM NaCl. Forty eight hours after
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Humanmyoblasts LHCNM2 (46) were grown inKMEM
199 Medium (Life Technologies) and DMEM (Life Tech-
nologies) in a 1:4 ratio supplemented with 20% foetal
calf serum (Life Technologies), 5 ng/ml human epithelial
growth factor (Life Technologies), 0.5 ng/ml bFGF, 0.2
Mdexamethasone (Sigma-Aldrich), 50g/ml fetuin (Life
Technologies) and 5 g/ml insulin (Life Technologies) in a
5% CO2 incubator at 37◦C. Differentiation was induced at
confluence by replacing the growth medium with DMEM
supplemented with 50 g/ml of gentamicin. Transfection
of human myoblasts were performed with Fugene HD
(Promega) following the manufacturer’s instructions and 48
h after transfection total RNA was immediately extracted
using Trizol (Invitrogen).
Primary H2KB IM2 mouse myoblasts (named ‘con-
trol’ hereafter) were conditionally immortalized with a
temperature-sensitive SV40 large T-antigen (tsA58) trans-
gene and derived from the ImmortoMouse. Mutated-
PABPN1 (H2KB-D7e named ‘Ala17’ hereafter) and wild-
type-PABPN1 (H2KB-WTa named ‘Ala10’) stable cells
lines were derived from IM2 cells line by transfection
with a plasmid expressing expanded-PABPN1 or wild-
type-PABPN1 respectively under the control of the hu-
man desmin locus control region and promoter to ensure
myotube-specific expression of the human PABPN1 trans-
gene (47). Cells were cultivated on matrigel coated support
(Corning) inDMEM, supplementedwith 20% foetal bovine
serum (Invitrogen), 0.5% chicken embryo extract (Seralab),
100 U/ml penicillin-streptomycin (Thermo Scientific), and
20 U/ml interferon- (Millipore) at 33◦C in a humidified
5%CO2 air atmosphere. For Ala17 and Ala10 cell lines, 500
g/ml of G418 (Life Technologies) was added to themedia.
Differentiation was induced when cells were fully conflu-
ent (90–100%) by changing medium to DMEM, 10% horse
serum and 100 U/ml penicillin-streptomycin at 37◦C in a
humidified 5% CO2 air atmosphere.
siRNA transfection was performed inHEK293T cells us-
ing PEI in 150 mM NaCl with 100 pmol of siRNA with
2 g of plasmid in a six-well plate. All siRNAs were syn-
thetized by Eurogentec. The control siRNAwas against Re-
nilla luciferase (PGL3) from Eurogentec. RNA and pro-
teins were collected 48 h after transfection. For H2KB
cells, siRNA transfection was performed using oligofec-
tamine (Life Technologies) according to the manufacturer’s
instructions in a 12-well plate with a final concentration of
60 pmol of siRNA. siRNA treatment in H2KB cells was
performed twice at 48 h interval before switching to differ-
entiation medium. RNA and protein extractions were per-
formed 5 days later.
Mice
A17.1 and A10.1 transgenic mice have been previously de-
scribed (25,48). Male A17.1, A10.1 mice and wild-type FvB
(WT) controls were generated by crossing the heterozygous
carrier strain A17.1 and A10.1 obtained from Rubinsztein’s
group (25) with FvB mice. The mice were genotyped by
PCR three to four weeks after birth. Wild-type FvB, A10.1
and A17.1 mice were housed in minimal disease facilities
(Royal Holloway, University of London) with food and wa-
ter ad libitum.
Isometric tension determination
T/pCa relation-ships were established as previously de-
scribed (49).
Skinning protocol. Muscles were chemically skinned by
overnight exposure at 4◦C to a skinning solution contain-
ing 10 mM MOPS, 170 mM potassium propionate, 2.5
mM magnesium acetate, 5 mM K2 EGTA, 2.5 mM ATP
(49). This procedure permeabilizes the sarcolemmal and the
transverse tubular membranes and allows the application
of activating solutions of various calcium and strontium
concentrations (pCa and pSr, with pCa = −log[Ca2+] and
pSr = −log[Sr2+]) directly to the contractile proteins. The
skinned biopsies were stored at –20◦C in a storage solution
(glycerol/skinning solution, 50/50, v/v) until analysis.
Solutions. The composition of all solutions was calculated
with the Fabiato computer program (50). Different solu-
tions were used in the experiments: a washing solution (10
mM MOPS, 185 mM potassium propionate, 2.5 mM mag-
nesium acetate); a relaxing solution identical to the skinning
solution; pCa and pSr activating solutions corresponding
to washing solution but with varying concentrations of free
Ca2+ or Sr2+ from CaCO3 or SrCl2, respectively, buffered
with EGTA and added in proportions to obtain the differ-
ent pCa values (7.0–4.2) or pSr values (5.0 and 3.4). ATP
was added to each solution to a final concentration of 2.5
mM. At the beginning of the experiment, each fiber was
bathed for 20 min in 2% Brij58 in relaxing solution, in or-
der to irreversibly eliminate the ability of the sarcoplasmic
reticulum of skinned muscles to sequester and release Ca2+.
Force measurements and effect of O-GlcNAcase inhibitors on
calcium properties. A 5 mm fiber segment isolated from
skinned biopsies was mounted in an experimental chamber.
On one end, the fiber was connected to a strain-gauge (force
transducer Fort 10, World Precision Instruments). The out-
put of the force transducer was amplified and recorded on
a graph recorder (Gould. model 6120) and simultaneously
analysed by computer software.
At the beginning of each experiment, the fibre was acti-
vated with the pSr 5.0 solution, followed by the pSr 3.4 so-
lution, to verify that the tested fibre was slow and not fast.
After bathing in the washing solution, the fiber was acti-
vated at a level P with various pCa solutions (from 7.0 to
4.8, with a step equal to 0.2 pCa units). Each steady state
submaximal P tension was followed immediately by a max-
imum contraction Po ensured by pCa 4.2 solution, a cal-
cium concentration that will saturate all troponin C sites.
The P tensions were expressed as a percentage of the max-
imal Po tension and reported as Tension/pCa (T/pCa) re-
lationships. Finally, the fibre was relaxed in the relaxing so-
lution. If force declined during a sustained contraction, or
decreased by more than 20% during the whole experiment,
or if T/pCa was not completely achieved, the fibres were
rejected from the analysis. Just after force measurements,
each fibre was resuspended in 10 l of Laemmli buffer, and
stored at -20◦C until further analysis.
The following parameters were determined from T/pCa
curves: the pCa50 value, corresponding to 50% of maximal
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the contractile apparatus for Ca2+; the threshold for acti-
vation by Ca2+(pCa threshold) as an indicator of the cal-
cium sensitivity of the contractile system; and the steepness
of the T/pCa reflecting the cooperativity between the differ-
ent regulatory proteins within the thin filament. The steep-
ness of the T/pCa was determined by the Hill coefficients
nH, calculated according to the following equation: P/Po=
([Ca2+]/K)nH/[1 + ([Ca2+]/K)nH]), where P/Po is the nor-
malized tension andK is the apparent dissociation constant
(pK= −logK= pCa50). All parameters were established in-
dependently for each fibre. Data are presented as means ±
SEM.Differences betweenmeans are considered significant
when P < 0.05, according to Student’s t-test.
Immunodetection of PABPN1 inclusions on muscle sections
Immunostaining of PABPN1 nuclear aggregates was per-
formed as previously described (51). Briefly, muscle sections
(5 or 10 m) were fixed in 100% cold acetone and pre-
incubated in 1M Potassium Chloride (KCl) solution for 1 h
to remove any soluble proteins, before incubation with rab-
bit polyclonal anti-PABPN1 (1/100, Epitomics) and anti-
dystrophin antibody (1/10, NCL-Dys1, Novocastra). Sec-
tions were further incubated with respective fluorescent sec-
ondary antibodies (Life Technologies) and stained with
Hoechst (Sigma-Aldrich) to visualize nuclei. The percent-
age of muscle fibre nuclei containing PABPN1 aggregates
was determined by counting the number of nuclei contain-
ing any PABPN1 staining compared to the total number of
myonuclei on the section.
PABPN1/SC35 immunostaining
H2KB cells were cultivated on Ibidi 35 mmDishes (Bioval-
ley). Immunofluorescence was performed at 5 days of dif-
ferentiation. Cells were washed once with PBS and fixed for
10 min with 4% paraformaldehyde–PBS. Cells were washed
with PBS–glycine 0.1 M for 15 min and incubated in 0.2%
Triton X-100 PBS, 3% BSA and 5% goat serum for 30
min. Detection of immunocomplexes was performed using
anti-PABPN1 (1/100, Epitomics) and anti-SC35 (1/1000,
Sigma) for 1 h. Cells were washed 3 times in 0.1% Triton–
PBS and incubated with goat anti-mouse and goat anti-
rabbit secondary antibodies conjugated to Alexa Fluor 488
and Alexa Fluor 555 respectively (Life Technologies).
Fluorescence in situ hybridization
RNA fluorescence in situ hybridization (FISH) was per-
formed using probes synthesized by PCR with specific
primers (one probe for exon 18 and three probes for in-
tron 15, see details in Supplementary Table S2) using the
Platinium Taq DNA Polymerase High Fidelity (Invitro-
gen) with a ratio of 1/6 of DIG-dUTP/dTTP (Roche) and
murine Tnnt3 expressing vector as template. PCR products
were loaded on agarose gels and purified using the Nucle-
ospin and PCR clean-up kit (Macherey-Nagel).
HEK293T cells were transfected with the murine Tnnt3
minigene expressing vector or with pCDNA3.1 using
PEI (2.5 g of DNA constructs using PEI in 150 mM
NaCl). Forty eight hours after transfection, cells were fixed
for 10 min in 4% PFA and rinsed with PBS. Cells were then
incubated with PBS 1% triton X-100 PBS for 30 min and
rinsed three times with PBS. The probe was denatured at
95◦C for 10min and put directly on ice. Cells were then incu-
bated with hybridization buffer (SSC 2×, 40% formamide,
0.2% BSA, 60 ng of yeast RNA) together with 60 ng of
Tnnt3 probe at 60◦C for 2 h. Then cells were washed with
0.1% Tween 20/PBS buffer for 30 min at 65◦C and three
times with PBS. This was followed by an incubation in 2%
SVF PBS for 30 min and with anti-digoxigenin-Rhodamine
Fab Fragments (Roche diagnostics) for 1 h in the dark. Cells
were washed three times in PBS and stained with Hoescht,
(Sigma Aldrich) to visualize nuclei. All experiments were
performed in RNAse free conditions.
H2KB cells (Ala17 and control) were differentiated dur-
ing 5 days on Ibidi 35mm Dish (Biovalley) and fixed for
10 min in 4% PFA rinsed with PBS. Cells were incubated
with PBS 1% triton X-100 for 30 min and rinsed three
timeswith PBS. Cells were incubatedwith pre-hybridization
buffer (SSC 2×, 40% formamide, 0.2% BSA) for 30 min.
The probe was denatured at 95◦C for 10 min and put imme-
diately on ice. Cells were then incubated with hybridization
buffer (SSC 2×, 40% formamide, 0.2% BSA, 60 ng of yeast
RNA) together with 60 ng of TNNT3 probe at 60◦C for 2
h. The cells were then washed with prehybridization buffer
for 30 min at 65◦C and three times with PBS 0.1% Tween 20
and three times with PBS.
This was followed by immunofluorescence staining for
PABPN1. Briefly, cells were incubated in PBS 2% SVF dur-
ing 30 min and with PABPN1 primary antibody (Epito-
mics) and SC35 antibody (Sigma) in the same buffer for 2
h at room temperature. Cell were washed three times with
PBS and incubated with the secondary antibodies Alexa
Fluor 488 and Alexa fluor 647 goat anti-mouse (Life Tech-
nology) and anti-digoxigenin-Rhodamine Fab Fragments
(Roche diagnostics) for 1 h in the dark. Cells were stained
with Hoescht, (Sigma-Aldrich) to visualize nuclei. All ex-
periments were performed in RNAse free conditions.
Western blotting
Proteins were extracted by sonicating cells in RIPA buffer
0.15 M NaCl, 0.1% SDS, 50 mM Tris (pH 8), 2 mM
EDTA and 10% Triton-X-100 with protease inhibitor cock-
tail (Complete, Roche Diagnostics). Similar quantities of
proteins were separated on 4–12%Bis–Tris gels (Invitrogen)
and transferred onto a nitrocellulose membrane for 1 h at
constant 30 V at 4◦C. Membranes were blocked by incuba-
tion in 5% milk or BSA in 0.1 M TBS, 0.1% Tween-20 for
1 h at room temperature under agitation. Membranes were
stained with primary antibodies directed against PABPN1
(1/1000, Epitomics), SC35 (1/1000, Millipore), SRP30a
(1/1000, Santa-Cruz), MBNL1 (1/1000, MB1a antibody,
gift from Glenn Morris), Flag-HRP (1/1000, Sigma) and
GAPDH–HRP (1/1000, Abcam). Membranes were then
incubated with appropriate secondary antibodies conju-
gated to HRP (except for Flag-HRP and GAPDH-HRP)
and the G:Box system (Syngene) was used to detect the sig-
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Image acquisition and analysis
Images were visualized using anOlympus BX60microscope
(Olympus Optical, Hamburg, Germany), digitalised using
a CCD camera (Photometrics CoolSNAP fx; Roper Scien-
tific) and analyzed using MetaView image analysis system
(Universal Imaging, Downington, PA, USA), MetaMorph
imaging system (Roper Scientific, Tucson, AZ, USA) soft-
ware, and ImageJ 1.44o (http://imagej.nih.gov/ij) for quan-
tification analysis.
Statistical analysis
All data are presented as mean values ± standard error of
themean (SEM) (cohort size stated per experiment). All sta-
tistical analyses were performed using either the Student’s t-
test, or the ANOVA one-way analysis of variance followed
by the Bonferroni post-test, usingGraphPad Prism (version
4.0b; GraphPad Software, San Diego California, USA). A
difference was considered to be significant at P < 0.05 (*),
P < 0.01 (**) or P < 0.001 (***).
RESULTS
TNNT3 exon 16 is downregulated in OPMD
To identify potential splicing defects in OPMD, we per-
formed a genome-wide transcriptomic analysis at the exon
level on RNA extracted from skeletal muscle biopsies of
OPMD patients (Table 1). For this study, we used stern-
ocleidomastoid muscles as a pre-symptomatic muscle, that
show both a typical clinical phenotype and a significant
amount of nuclear aggregates compared to age-matched
control subjects (Figure 1A). Forty six missplicing events
were found in 39 distinct genes, including 12 cassette exon
defects (Supplementary Table S1 and Figure S1A). Among
them the most significantly deregulated mRNA (highest
splicing fold change index) encodes a muscle-specific pro-
tein, the human Troponin T type 3 (TNNT3) (Table 2).
The TNNT3 transcript contains 18 exons; its pre-mRNA
is extensively spliced with two mutually exclusive exons, 16
() and 17 (), included at the 3′ end (52–54) (Figure 1B).
Exon 16 was found to be downregulated in OPMD samples
(Supplementary Figure S1A), leading to an imbalanced ra-
tio of these mutually exclusive exons. This was confirmed
by RT-PCR on sternocleidomastoid and quadriceps mus-
cle biopsies from OPMD patients, with a strong decrease in
the level of the exon 16 isoform expression (Figure 1C and
D). Splicing defects of RECK exon 8 (Reversion-Inducing-
Cysteine-Rich Protein With Kazal Motifs) and ZCCHC11
exon 8 (Zinc Finger CCHCDomain-Containing Protein 11
or TUT4)––whichwere respectively hits numbers 2 and 3 on
the exon array analysis (Table 2 and Supplementary Figure
S1A)–were also confirmed by qRT-PCR on sternocleido-
mastoid muscle biopsies (Supplementary Figure S1B). This
is the first time that misregulated alternative splicing events
have been described in OPMD.
TNNT3 splicing defect is linked to the presence of aggregates
We checked the splicing pattern of Tnnt3 in a murine cell
model ofOPMD, namely theH2KB-D7e cells (47). Primary
H2KB-IM2 cells are conditionally immortalizedmousemy-
oblasts derived from the ImmortoMouse (55) and H2KB-
D7e are cells stably derived from the H2KB-IM2 cell line by
transduction with an expanded Flag-tagged PABPN1 con-
struct under the control of the human desmin locus con-
trol region and promoter. This ensures that the human exp-
PABPN1 transgene will only be expressed in differentia-
tion conditions (Supplementary Figure S2A). For clarity,
the H2KB-IM2 and -D7e will be called hereafter ‘control’
and ‘Ala17’ muscle cells respectively. In differentiation con-
ditions, these Ala17 cells contain a large number of nuclear
aggregates present in more than 50% of the nuclei ((47) and
Figure 2E). In control cells, the Tnnt3 exon 16 isoform is
absent at day 1, but progressively increases during differ-
entiation. Interestingly, in Ala17 cells at both 3 and 5 days
of differentiation, we observed the same splicing defect as in
humanOPMDsamples with a strong decrease in the level of
the Tnnt3 exon 16 isoform compared to control cells (Fig-
ure 2A and B). Since the expression of the Tnnt3 exon 16
isoform increases during differentiation we verified that the
splicing defect in Ala17 cells was not due to a delay in dif-
ferentiation. Light microscopy visualization showed com-
parable fused myoblasts in control and OPMD cell lines
at 5 days of differentiation (Supplementary Figure S2B).
In addition, myogenin and myosin expression levels were
equivalent in both Ala17 and control cells during the time
course of differentiation (days 1, 3 and 5). We also checked
the alternative splicing of Bin1 exon 10, which is known
to be regulated during muscle differentiation (56) and the
splicing pattern was similar in both conditions, further con-
firming that the differentiation kinetics were similar in con-
trol and Ala17 cells (Supplementary Figure S2C). To un-
derstand the link between PABPN1 nuclear aggregates and
the splicing defect, we reduced PABPN1 expression in dif-
ferentiated Ala17 cells using RNA interference. The reduc-
tion of PABPN1 expression by 50% at mRNA and protein
level (Figure 2C-D) drastically reduced the percentage of
nuclei containing nuclear aggregates from 60% to 10% (Fig-
ure 2E). This led to the rescue of the splicing defect in differ-
entiated siRNA-treated Ala17 cells (Figure 2F). Several hy-
potheses have been made regarding the role of PABPN1 ag-
gregates in the pathogenesis of the disease, one of them be-
ing the sequestration of PABPN1 itself, leading to a loss of
function. Transfection of siRNA against PABPN1 in con-
trol cells––to mimic a loss of function––did not modify the
level of exon 16 isoform (Figure 2F). Neither did the addi-
tion of a wild-type functional PABPN1 expressing vector in
Ala17 cells (data not shown), suggesting that TNNT3 splic-
ing defect is not linked to the level of available PABPN1
itself. To further reinforce the crucial role of the aggregate
we checked the splicing defect in H2KB-WTa (Ala10 cells),
overexpressing wild-type Flag-tagged PABPN1 at the same
level as in Ala17 cells and containing aggregates in differen-
tiation ((47) and SupplementaryFigure S3A-B): the splicing
defect was confirmed in this differentiated cell line as well
(Supplementary Figure S3C and D). Together these results
strongly suggest a direct link between the presence of nu-
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Figure 1. Splicing of TNNT3 mutually exclusive exons 16 and 17 is deregulated in oculopharyngeal muscular dystrophy. (A) Left: PABPN1 staining
followingKCl treatment revealed intranuclear aggregates in OPMDmuscle biopsies (red: dystrophin, green: PABPN1, blue: dapi). Aggregates are indicated
with an arrow. On the bottom right panel, is presented a control biopsy - no aggregates are present. Scale bar = 50 m. Right: Quantification of nuclear
aggregates showed 6.7–16.7% PABPN1 aggregates (mean 12%) in myonuclei from OPMD patients. ** indicates P < 0.01. (B) Schematic representation of
the exon structure of TNNT3 pre-mRNA. pA: polyadenylation site. Exons 16 and 17 are highlighted in grey. The two mutually exclusive exons are both 41
bp long encoding each a short 14 amino acid peptide in the C-terminal of the protein. Arrows on exons 15, 16 and 17 indicate the forward (TNNT3-ex15-
FWD) and two reverse (TNNT3-ex16-REV-108 and TNNT3-ex17-REV-131) primers used to amplify and discriminate by PCR the two TNNT3 transcript
isoforms. (C andD) TNNT3 exon 16 is downregulated in OPMD skeletal muscle biopsies with (C). Left: RT-PCR analysis of endogenous TNNT3 exon 16
and 17 isoforms from human sternocleidomastoid skeletal muscle biopsies of normal adult individuals (CTRL; n= 4) andOPMDpatients (OPMD; n= 5).
Right: quantification of respective exon 16 and 17 inclusions in TNNT3mRNA. ***indicates P< 0.001 and (D) RT-PCR analysis of endogenous TNNT3
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Figure 2. Tnnt3 splicing defect is rescued by reducing the amount of aggregates in murine myoblasts. (A) Tnnt3 exon 16 level is downregulated in OPMD
murine myoblasts. RT-PCR analysis of endogenous Tnnt3 exon 16 and 17 isoforms from CTRL and OPMD (Ala17) murine myoblasts after 1, 3 and
5 days of differentiation - primary CTRL mouse myoblasts are conditionally immortalized with a temperature-sensitive SV40 large T-antigen (tsA58)
transgene and derived from the ImmortoMouse. Mutated-PABPN1 (Ala17) stable cells lines derive from CTRL cells line and express expanded-PABPN1.
Below: quantification of respective exon 16 and 17 inclusions in Tnnt3 mRNA. (B and C) siRNA treatment against PABPN1 (siPAB#1 and siPAB#2) in
differentiated Ala17 cells reduce the level of PABPN1 at mRNA level, as shown by quantitative RT-PCR (** indicates P < 0.01 compared to siCTRL,
transfections are performed in triplicate), and (D) at protein level as shown by representative Western blot. (E) Left: The amount of nuclear aggregates
was drastically reduced by siPAB treatment. The histogram indicates the percentage of nuclei containing PABPN1 aggregates classified based on the
number of aggregates per nuclei (1, 2, 3 or more than 3). An average of 100 nuclei in myotubes were counted on random fields. Right: Representative
immunofluorescence of nuclei with 0, 1, 2, and >3 PABPN1 nuclear aggregates. Scale bar = 5 m. (F) Rescue of Tnnt3mRNA splicing defect with siRNA
against PABPN1 (siPAB#1 and #2) compared to a siRNA control (siCTRL) in differentiated Ala17 cells. Quantification of RT-PCR analysis of Tnnt3











ollege London) user on 19 M
arch 2019
Nucleic Acids Research, 2016, Vol. 44, No. 22 10937
Table 2. Splicing defects are present in oculopharyngeal muscular dystrophy including alteration of TNNT3 alternative splicing of exon 16 and 17. Exon
array revealed several splicing defects, including 12 cassette exon events. TNNT3 was the first hit on the array with the highest splicing fold change index.
A manual inspection allowed the filtering and classification of exons predicted to be differentially included.
GENE STABLE ID Gene symbol Fold-change splicing index P-value splicing index Confidence
GSHG0004534 TNNT3 3,55 1,03E-02 +++
GSHG0030112 RECK 2,12 2,03E-02 +++
GSHG0002105 ZCCHC11 2,17 1,42E-02 ++
GSHG0008422 SPG20 2,09 1,80E-02 ++
GSHG0030642 RFX3 2,07 3,70E-02 ++
GSHG0008586 UGGT2 2,04 4,80E-02 ++
GSHG0008374 USP12 2,53 1,41E-02 +
GSHG0017444 SMC6 2,49 7,97E-04 +
GSHG0022278 ABCC5 2,33 3,04E-02 +
GSHG0031771 WDR44 2,24 1,24E-02 +
GSHG0007569 STAC3 2,15 4,80E-02 +
GSHG0023986 SLC30A5 2,26 1,66E-02 +
SC35 splicing factor regulatesTNNT3mutually exclusive ex-
ons
To determine which splicing factor is involved in the
regulation of TNNT3 mutually exclusive exons, a mini-
gene containing exons 16 and 17 of human TNNT3 bor-
dered by exon 15, 18 and their intronic regions (Figure
3A) was cloned from human genomic DNA in a plas-
mid expression vector. This minigene construct was co-
transfected into HEK293T cells––which do not express
TNNT3––together with various vectors expressing well-
characterized splicing regulatory factors. These included
members of the hnRNP, SR, MBNL and CELF families
andwere selected using prediction software (SpliceAid2 and
ESEFinder publically available at http://193.206.120.249/
splicing tissue.html and http://rulai.cshl.edu/cgi-bin/tools/
ESE3/esefinder.cgi?process=home respectively) (57,58) (Ta-
ble 3). Fifteen selected splicing factors were tested by co-
transfection with the TNNT3 minigene expression vec-
tor. GFP was used to monitor expression and transfec-
tion efficiency (Supplementary Figure S4A), and we fur-
ther confirmed by western-blotting the level of expression
in HEK293T cells for several of them (Figure 3D and Sup-
plementary Figure S4B). Of the 15 splicing factors, only the
co-expression of SC35 (also called SRSF2) or hnRNPK to-
gether with theTNNT3minigene expression vector induced
a significant increase in exon 16 inclusion (Figure 3B). Us-
ing the same approach, we also confirmed that PABPN1
overexpression itself did not modify the level of exon 16
(Supplementary Figure S4C and D). As the splicing de-
fect is present in both human and murine OPMD samples
(Figures 1C and D and 2A), the same approach was ap-
plied using a murine Tnnt3 exons 15–18 minigene expres-
sion vector. In this situation, only the co-transfection of the
SC35 expression vector significantly modified the inclusion
of exon 16 (Figure 3C). Finally in human myoblasts, only
the transfection of the SC35 expression vector led to the
upregulation of the exon 16 isoform when co-transfected
with the human TNNT3 minigene expression vector (Fig-
ure 3E), confirming that SC35 is the most probable splic-
ing factor candidate for the regulation of exon 16 inclusion.
SC35 is also a well-known constituent of nuclear speckles
(59) involved in pre-mRNA splicing (60). The transfection
of cells with SC35 results in an upregulation of the exon
16 isoform, which is downregulated in OPMD patients or
cells. Although the level of SC35 itself is not downregulated
in OPMD samples when compared to control samples (Fig-
ure 3F), downregulation of the exon 16 isoform can bemim-
icked by depletion of SC35 expression level using RNA in-
terference in HEK293T cells transfected with the TNNT3
minigene (Figure 3G-I). In contrast, the downregulation of
SRP30a (ASF/SF2, a splicing factor related to SC35 (61))
or MBNL1 (which regulates the splicing of TNNT3 fetal
exon (62,63)) by RNA interference did not recapitulate this
splicing defect found inOPMDor in SC35-knockdown cells
(Supplementary Figure S4E and F). These results demon-
strate that the splicing regulation of TNNT3 mutually ex-
clusive last exons is strongly dependent on SC35 and sug-
gest that in OPMD TNNT3 pre-mRNA and SC35 splicing
factor are somehow dissociated.
TNNT3 pre-mRNA is trapped in nuclear aggregates
Aggregates are formed by the accumulation of misfolded
PABPN1 in muscle nuclei. Interestingly, it is already known
that these PABPN1 aggregates are delocalized from SC35-
nuclear speckles (19,47,64). By immunostaining we con-
firmed the delocalization of PABPN1 aggregates and SC35
nuclear splicing domains in differentiated Ala17 OPMD
cells as opposed to the co-localization of PABPN1 and
SC35 observed in control cells (Figure 4A and Supplemen-
tary Figure S5A). A recent study proposed that growing
PABPN1 aggregates gradually deplete SC35-nuclear speck-
les of poly(A) RNA/PABPN1 complexes, thus interfering
with the normal trafficking and post-transcriptional pro-
cessing of poly(A) mRNA in speckles (64). We took advan-
tage of the Ala17 cells where Tnnt3 splicing defect and nu-
clear aggregates are both present and we analysed the lo-
calization of Tnnt3 pre-mRNA in these cells, by perform-
ing fluorescent in situ hybridization (FISH). Using probes
targeting specifically exon 18 (ex18) or intron 15 (int15) of
Tnnt3 pre-mRNA (Supplementary Figure S6), we observed
a co-localization of Tnnt3 pre-mRNA with PABPN1 in nu-
clear aggregates (Figure 4B and C and Supplementary Fig-
ure S5B). Hence, the pre-mRNA of Tnnt3 is physically de-
localized from SC35-nuclear speckles. Therefore, we specu-
lated that the splicing defect is a consequence of the spatial
dissociation of SC35 andTnnt3 pre-mRNA, the latter being
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Figure 3. SC35 regulates alternative splicing ofTNNT3 exon 16 and 17. (A) Schematic representation of the humanTNNT3minigene containing both exons
16 and 17 bordered by exons 15 and 18 including full downstream and upstream intronic sequences (sizes are indicated in italic above). (B) and (C) SC35
overexpression increases inclusion of TNNT3 exon 16. Quantification of RT-PCR analysis of TNNT3 exon 16 (% exon 16) inclusion following respectively
human (B) and murine (C) exons 15–18 minigene expressing vector cotransfection in HEK293T cells together with 15 different vectors expressing splicing
factors. Histograms represent the mean of at least three independent transfections and are depicted as the percentage of mRNA containing TNNT3 exon
16. Error bars indicate S.D. and # indicates statistical ANOVA difference compared to the minigene only condition. (D) A western-blot showing SC35
overexpression in HEK293T cells transfected with SC35 expressing vector fused with GFP compared to untransfected cells. (E) SC35 overexpression
increases inclusion of TNNT3 exon 16 in human myoblasts. RT-PCR analysis after transfection of the human TNNT3minigene into the human myoblast
cell line LHCNM2 together with several splicing factors. (F) RT-qPCR on human muscle biopsies demonstrating that the expression level of SC35mRNA
is similar in control and OPMD samples. (G) Representative Western blot showing SC35 extinction in HEK293T cells transfected with siRNA against
SC35 compared to HEK293T cells transfected with siRNACTRL. (H–I) SC35 extinction mimics theTNNT3 splicing defect observed in OPMD. RT-PCR
analysis of the TNNT3minigene cotransfected with a siRNA against SC35 (siSC35#1 and #2), a siRNA against luciferase as a control (siCTRL), or with
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Figure 4. Tnnt3 pre-mRNA is trapped in PABPN1 aggregates. (A) PABPN1 is localized in SC35-nuclear speckles in control conditions and delocalized
from SC35-nuclear speckles with nuclear aggregate formation in OPMD (Ala17). Immunofluorescence of PABPN1 and SC35 in control and OPMD
(Ala17) H2KB cell lines. Scale bar = 5 m. Single cell magnified of Ctrl and Ala17 cells are presented in Supplementary Figure S5. (B and C) Tnnt3
pre-mRNA is present in PABPN1 nuclear aggregates. (B) Representative image of RNA fluorescence in situ hybridization (FISH) using a Digoxigenin
probe targeting exon 18 of TNNT3 mRNA (red) coupled to immunofluorescence detection of PABPN1 (green) and counterstained with Hoechst (blue)
on fixed 5-day differentiated Ala17 cells. Scale bar = 10 m. (C) Different representative images of FISH using a probe targeting exon 18 (ex18, left) or
intron 15 (int15, right) of TNNT3 pre-mRNA coupled to immunofluorescence detection of PABPN1 on fixed 5-day differentiated Ala17 cells. Pre-mRNA
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Table 3. List of splicing factors (SF) able to regulate exon 16 and 17 of TNNT3 pre-mRNA using prediction sites. Splicing enhancers are in blue and
splicing silencers are in red
Calcium sensitivity is decreased in slow fibers of OPMDmus-
cles
TNNT3 pre-mRNA is intensively spliced and finely regu-
lated; it is suggested that the abundance in the ratio of the
different isoforms participates to muscle plasticity (54). In
order to investigate the physiopathological consequences
of this splicing defect, we used a mouse model of OPMD,
the A17.1 mouse. This model was generated by the expres-
sion of alanine expanded mammalian PABPN1 (PABPN1-
17ala) specifically inmuscles; it reproduces the disease char-
acteristics, namely progressive muscle weakness and for-
mation of nuclear aggregates containing mutant PABPN1
in muscles (25,48). Interestingly, we found the same splic-
ing defect in the slow soleus muscle of this A17.1 OPMD
mousemodel (Figure 5A), where nuclear aggregates are also
present (Figure 5B), whereas this splicing defect was absent
in the soleus of the control A10.1 mouse (overexpressing
wild-type PABPN1 (25)), where nuclear aggregates are ab-
sent (Supplementary Figure S7). These data strengthen the
claim of a direct link between the splicing defect and the
presence of nuclear aggregates. TNNT3 is a subunit of the
trimeric troponin complex, which regulates skeletal muscle
contraction in response to calcium (65). In vitro assays with
recombinant proteins already demonstrated that a differ-
ence in the ratio of isoforms including exon 16 or 17 led to
alterations in muscle fibre calcium affinity, a key parame-
ter involved in the modulation of force contraction (54,66).
Indeed, while numerous reports have demonstrated the pre-
dominant role of the calcium sensor Troponin C of the tro-
ponin complex in the modulation of calcium sensitivity and
affinity, it has been clearly established that TNNT3 is also
involved in the modulation of these mechanisms (67). We
took advantage of the soleus of the A17.1 mouse, which
presents the unbalanced ratio of Tnnt3 mutually exclusive
exons to look at the functional consequences of the TNNT3
splicing defect. We first calculated the pCa/tension rela-
tionship in order to analyse whether the activation param-
eters of muscle fibre tension by calcium could be altered in
OPMD muscles. The Tension/pCa relationship performed
on isolated skinned fibres from murine soleus muscles re-
vealed a decrease in the calcium affinity of slow OPMD
muscle fibres compared to slow control muscle fibres (pCa
of 5.85 ± 0.04 and 6.02 ± 0.04 respectively, P < 0.05) (Fig-
ure 5C). This decrease in calcium affinity can be clearly re-
lated to the expression of the exon 17 containing isoform
instead of the exon 16 isoform, since previous data has
shown that the Tnnt3 exon 17 containing isoform had a
lower calcium affinity than the exon 16 isoform (66). Our
data demonstrate that a decrease in calcium handling is a
functional consequence of the decrease in exon 16 Tnnt3
isoform in slow fibres, which are the predominant fibre type
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Figure 5. Splicing defect in OPMD mouse induces decreased calcium sensitivity. (A) Tnnt3 splicing defect is present in OPMD mouse model. RT-PCR
analysis of endogenousTnnt3 exons 16 and 17 isoforms in soleus (Sol) muscles of wild-type (WT) andA17.1 (OPMD)mice. (B) PABPN1 staining following
KCl treatment revealed intranuclear aggregates in the soleus muscle of A17.1 mouse (red: dystrophin, green: PABPN1, blue: dapi), whereas no aggregate
are observed in control mice. Aggregates are indicated with an arrow (see also inset boxes). Scale bar = 30 m. (C) Deregulation of Tnnt3 exon 16 and 17
induces decreased calcium sensitivity in mice slow fibers, as measured by pCa/Tension relationship. * indicates P < 0.05, ** indicates P < 0.01.
DISCUSSION
Like many triplet expansion disorders, OPMD is character-
ized by the presence of insoluble nuclear aggregates in mus-
cle fibres. However the exact role and contribution of these
PABPN1 aggregates to the clinical phenotype in OPMD
is still debated (1). In this study, we clearly illustrate that
PABPN1 nuclear aggregates have at least one toxic func-
tion as they lead to a specific splicing defect: PABPN1 ag-
gregates are able to trap the muscle-specific TNNT3 pre-
mRNA, driving it outside of the nuclear speckles, leading
to altered SC35-mediated splicing. This trapping leads to
a defect in the splicing regulation of the TNNT3 mutu-
ally exclusive exons 16 and 17 in OPMD samples compared
to controls. This is the first demonstration of splicing de-
fects in OPMD. Poly(A) RNA were previously observed
in PABPN1 nuclear aggregates using oligo-dT probes (18–
19,64); here we additionally demonstrate that PABPN1 nu-
clear aggregates are able to sequester a pre-mRNA lead-
ing to its missplicing. Whether this muscle-specific RNA
plays a role as a potential scaffold for aggregate forma-
tion in a similar way to architectural RNAs (arcRNA)
for nuclear domains such as paraspeckles or stress bod-
ies (68) remains to be further investigated. Nuclear speck-
les are essential nuclear compartments involved in post-
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Figure 6. Molecular mechanism of splicing deregulation in OPMD. Molecular model of TNNT3 mRNA splicing defect in OPMD: in healthy condition,
mutually exclusives exons of TNNT3 pre-mRNA are regulated by SC35 splicing factor favouring exon 16 inclusion. In OPMD condition, TNNT3 pre-
mRNA is delocalized from SC35 nuclear speckles by PABPN1 nuclear aggregates trapping resulting in a missplicing of exon 16 and a decreased calcium
affinity of muscle fibres.
tures are enriched in poly(A) RNA, in many pre-mRNA
splicing factors including snRNP (small nuclear ribonucle-
oprotein particles) and in SR splicing factors such as SC35
(69). PABPN1 is found in the nucleoplasm excluding the
nucleolus and is concentrated mainly in nuclear speckles
where it participates in mRNA metabolism. This localiza-
tion of PABPN1 in nuclear speckles requires the binding to
poly(A) RNA (19,29,70–71). Previous studies have shown
that PABPN1 nuclear aggregates originate at the edge of
the speckles and gradually delocalize outside of these com-
partments, together with a gradual depletion of poly(A)
RNA from speckles (19,64). It has been suggested that
Pab2 (fission yeast ortholog of mammalian PABPN1) asso-
ciates with pre-mRNA co-transcriptionally prior to 3′ end
processing/polyadenylation (72). In addition, pre-mRNA
introns located at the 3′ end of multiple intron transcripts
are more frequently spliced post-transcriptionally, presum-
ably because transcription termination and cleavage at the
polyadenylation site occurs before the splicing machinery
manages to catalyse their removal (73). It is well estab-
lished that the different steps of pre-mRNA processing (5′
cap, splicing, 3′ end processing) are connected and influence
each other (74,75). The splicing defect that we identified is at
the 3′ end of the TNNT3 pre-mRNA and we therefore pro-
pose that during the processing of TNNT3 pre-mRNA, the
binding of PABPN1 to its 3′ end for further cleavage and
polyadenylation induces, in the case of OPMD, a gradual
delocalization of the complex pre-mRNA/PABPN1 from
SC35-nuclear speckles. This delocalization induces a miss-
plicing of the last exons of TNNT3 with the production of
a modified protein that has a negative effect on muscle con-
traction. Indeed, the imbalanced ratio of TNNT3 exons 16
and 17 induced a decrease in calcium sensitivity with phys-
iopathological consequences at the level of the muscle fibre
(see Figure 6 for a molecular model).
In this study, we have exploited different OPMD cell and
animalmodels to decipher the exactmechanism, which con-
trols the splicing defect observed in TNNT3. These mod-
els, based on expanded PABPN1 overexpression, reproduce
pathological characteristics found in OPMD patients, in-
cluding the presence of nuclear aggregates. The overexpres-
sion is not ideal, since this is absent in OPMD patients (76).
In the present study, we therefore performed several experi-
ments to clearly dissociate aggregation from overexpression
in these models. Using both RNAi and transfection sys-
tems to modify the level of PABPN1, we confirmed that
the splicing defect reproduced in OPMD models is solely
due to the presence of aggregates and not to the level of
PABPN1 itself. Indeed, neither the reduction of PABPN1
levels in control IM2 cells, nor the transfection in Ala17
cells with an exogenous PABPN1 expression vector to po-
tentially compensate for a loss of function, nor the silenc-
ing or overexpression of PABPN1 in HEK293T cells trans-
fected with the TNNT3 minigene, were able to modify the
splicing pattern of TNNT3. In addition, since PABPN1 it-
self is an aggregate-prone protein, it is well known that the
artificial overexpression of wild-type PABPN1 protein is
able to induce in cells the formation of nuclear aggregates
(77,78). For example, it has previously been demonstrated
that the H2KB-WTa cells (named Ala10 cells here), overex-
press wild-type PABPN1 and do contain around 20% nu-
clear aggregates (47). That the same phenotypes can be in-
duced following expression of normal or mutant protein
in Drosophila models of other disorders has also been re-
ported previously (e.g. Parkinson’s disease (79)). We used
this cell model to further verify our mechanism and as ex-
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the splicing defect in these cells. Interestingly in the soleus
of A10.1 mice we were unable to detect aggregates and log-
ically the splicing defect was absent. Altogether these data
again emphasize the pivotal role of nuclear aggregates in the
mechanism.
Similar findings regarding alanine repeats and subnu-
clear protein localization have been recently observed with
the RNA-binding motif protein 4 (RBM4) (80). Alterna-
tive splicing defects have previously been observed in other
trinucleotide repeat disorders including myotonic dystro-
phy (41). However, this is the first time that a splicing de-
fect, with a misregulation of mutually exclusive last exons
of the muscle specific TNNT3 mRNA, has been identified
in OPMD. In the spliceopathies described so far, alternative
splicing misregulation is in most cases due to an abnormal
activity of an RNA splicing factor, for example, functional
loss ofMBNLproteins due to their sequestration by nuclear
mutant RNA in myotonic dystrophy (81). This abnormal
activity often results from splicing factors being misplaced
from their natural location within the cell, highlighting the
importance of the spatial distribution of the intracellular
mRNA and splicing factors. We describe here a different
mechanism directly linked to the presence of nuclear aggre-
gates: the splicing defect is due to the spatial separation of
the deregulated RNA from its splicing factor. Although the
generic nature of this alternative mechanism remains to be
demonstrated, it may play a role in various other diseases
with nuclear inclusions or foci containing an RNA binding
protein, as shown here for OPMD.
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Supplementary Data are available at NAR Online.
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